USA As Represented by Secretary of the Navy

US Government As Represented by the Secretary of the Army

Decisionq Corporation

Thomas A Davis

Eric Elster

Jonathan A Forsberg

John S Eberhardt, Iii

Trevor S Brown

Doug K Tadaki

Alexander Stojadinovic

Jason Hawksworth

Douglas H Robinson

Roslyn Bernstein Mannon

Khairul Anam

Douglas K Tadaki

Abha A Saini

John P Chute

Dennis J Chute

Steven Kessler

An embodiment of the invention provides a method for determining a patient-specific probability of disease. The method collects clinical parameters from a plurality of patients to create a training database. A fully unsupervised Bayesian Belief Network model is created using data from the training database; and, the fully unsupervised Bayesian Belief Network is validated. Clinical parameters are collected from an individual patient; and, such clinical parameters are input into the fully unsupervised Bayesian Belief Network model via a graphical user interface. The patient-specific probability of the healing rate of an acute traumatic wound is output from the fully unsupervised Bayesian Belief Network model and sent to the graphical user interface for use by a clinician in pre-operative planning. The fully unsupervised Bayesian Belief Network model is updated using the clinical parameters from the individual patient and the patient-specific probability of the healing rate of an acute traumatic wound.

Clinical decision model

A method inducing chimerism and allograft tolerance by co-infusion of stem/progenitor-like cells and donor cells, wherein the donor cells can be bone marrow cells. The method also comprises the conditioning comprising depletion of CD4+ and CD8+ T-cells and administration of low doses of anti-neoplastic drugs. The inventive method comprises an aspect wherein allograft tolerance is induced without systemically suppressing the immune system.

Allograft tolerance induction

An embodiment of the invention provides a method for determining a patient-specific probability of transplant glomerulopathy. The method collects clinical parameters from a plurality of patients to create a training database. A fully unsupervised Bayesian Belief Network model is created using data from the training database; and, the fully unsupervised Bayesian Belief Network is validated. Clinical parameters are collected from an individual patient; and, such clinical parameters are input into the fully unsupervised Bayesian Belief Network model via a graphical user interface. The patient-specific probability of transplant glomerulopathy is output from the fully unsupervised Bayesian Belief Network model and sent to the graphical user interface for use by a clinician in pre-operative planning. The fully unsupervised Bayesian Belief Network model is updated using the clinical parameters from the individual patient and the patient-specific probability of transplant glomerulopathy.

Bayesian clinical decision model for determining probability of transplant glomerulopathy

A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD34 CD38 cells consistent with the PMVEC system is disclosed. HUBEC were isolated from cadaveric donors, passed in primary culture, cloned and found to be Von Willebrand Factor positive. Cultivation of purified bone marrow CD34 cells on HUBEC monolayers supplemented with GM-CSF&plus;IL-3&plus;IL-6&plus;SCF&plus;flt-3 ligand caused a 14.5-fold increase in total cells, an 6.6-fold increase in CD34 cells, and, most remarkably, a 440-fold increase in CD34 CD38 cells after 7 days. Further, CFU-GM production increased 15.1-fold, BFU-E increased 8-fold, and CFU-Mix increased 5.2-fold. Optimal generation was dependent upon the continued presence of exogenous supplied cytokines. Moreover, we found that non-brain human endothelial cells isolated from the same donors supported neither the expansion nor the maintenance of human CD34 CD38 cells.

Human brain endothelial cells and growth medium and method for expansion of primitive CD34&plus;CD38-bone marrow stem cells

The present invention relates to a method of amplifying in vitro stemcells. In this method hematopoietic CD34.sup.+ stem and progenitor cells are isolated from human bone marrow and contacted with endothelial cells. The contacted stem cells and endothelial cells are cultured in the presence of at least one cytokine in an amount sufficient to support amplification/expansion of the hematopoietic CD34.sup.+ stem and progenitor cells. This method produces increased yields of hematopoietic CD34.sup.+ stem and progenitor cells which can be used in human therapeutics.

In vitro amplification/expansion of CD34.sup.+ stem and progenitor cells

Growing community of inventors

Oak Hill, VA, United States of America

Thomas A Davis